Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (bħala fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - aġenti antineoplastiċi - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. poliċitemija vera (pv)jakavi huwa indikat għall-kura ta ' pazjenti adulti b'poliċitemija vera li huma reżistenti jew intolleranti għal hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.